Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celltransplantchemotherapysmallallogeneic
  Phrases that lowered it: amlabusethe trialdrugswithin weeks
• Sponsor's past termination rate: 33.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 45.4% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 43 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 177 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 92.7% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 10260 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia NCT02996474 · started 2016 · scored riskier than 50% of active trials completed
• MRD-guided Treatment in NPM1mut AML Patients NCT03769532 · started 2019 · scored riskier than 91% of active trials terminated
• High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML NCT02768792 · started 2016 · scored riskier than 95% of active trials completed
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation NCT02577406 · started 2015 · scored riskier than 92% of active trials completed
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia NCT04752163 · started 2021 · scored riskier than 94% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.